Results 231 to 240 of about 3,250,923 (288)

Engineered extracellular vesicles enriched with the miR‐214/199a cluster enhance the efficacy of chemotherapy in ovarian cancer

Molecular Oncology, EarlyView.
Loss of the miR‐214/199a cluster is associated with recurrence in ovarian cancer. Engineered small extracellular vesicles (m214‐sEVs) elevate miR‐214‐3p/miR‐199a‐5p in tumor cells, suppress β‐catenin, TLR4, and YKT6 signaling, reprogram tumor‐derived sEV cargo, reduce chemoresistance and migration, and enhance carboplatin efficacy and survival in ...
Weida Wang, Ayesha Alvero, Yi Qin, Mingjin Wang, Alexandra Fox, Yanfeng Li, Michael Millman, Amy Kemper, Gil Mor, Xian Shuang Liu, Michael Chopp, Zheng Gang Zhang, Yi Zhang   +12 more
wiley   +1 more source

Pregnancy outcomes in women at high risk of preterm birth receiving a vaginal cervical cerclage with, or without, progesterone: A retrospective, secondary analysis of the C-STICH randomised controlled trial data. [PDF]

PLoS Med
Hodgetts Morton V, Morris K, Toozs-Hobson P, Middleton L, Pilarski N, Bell L, Hogg M, Man R, Israfil-Bayli F, Shennan A, Simpson N, Lees C, Moakes C.   +12 more
europepmc   +1 more source

IMPDH inhibition enhances cytarabine efficacy in SAMHD1‐expressing leukaemia cells via guanine nucleotide depletion

Molecular Oncology, EarlyView.
Cytarabine is a key therapy for acute myeloid leukaemia (AML), but its efficacy is limited by the dNTPase SAMHD1, which hydrolyses its active metabolite. Screening nucleotide biosynthesis inhibitors revealed that IMPDH inhibitors selectively sensitise SAMHD1‐proficient AML cells to cytarabine.
Miriam Yagüe‐Capilla, Christopher Dirks, Caroline Eiden, Sonja K. Fesenmayer, Femke M. Hormann, Yolande Klootsema, Ingrid Lilienthal, Si Min Zhang, Nikolas Herold, Sean G. Rudd   +9 more
wiley   +1 more source

The timeliness of health plan drug coverage policy changes to FDA label revisions. [PDF]

Health Aff Sch
Enright DE, Beinfeld MT, Brennan CH, Lin Y, Motyka JD, Campbell JD, Chambers JD.   +6 more
europepmc   +1 more source

Keratin 19 as a prognostic marker and contributing factor of metastasis and chemoresistance in high‐grade serous ovarian cancer

Molecular Oncology, EarlyView.
Keratin 19 (KRT19) is overexpressed in high‐grade serous ovarian cancer with high levels of Kallikrein‐related peptidases (KLK) 4–7 and is associated with poor survival. In vivo analyses demonstrate that elevated KRT19 increases peritoneal tumour burden.
Sophia Bielesch, Isabel Vogel, Sina Nokodian, Johanna Moeller, Antonia Blechschmidt, Vicky Hecht, Vanessa Kuentzel, Katharina Thiedig, Melissa Schwab, Oliver Schilling, Holger Bronger, Marion Kiechle, Viktor Magdolen, Tobias Dreyer   +13 more
wiley   +1 more source

A comparative analysis of health technology assessment decision-making for cancer drugs in Germany and England. [PDF]

Front Public Health
He J, Wei H, Mo Q, Liu Y, Li X, Yang Y, Tian L.   +6 more
europepmc   +1 more source

Reassessing IgRT in CLL: evidence still unconvincing. [PDF]

Blood Adv
Lesan V, Munteanu C.
europepmc   +1 more source

Cardiovascular Safety Signals of Oral Versus Topical Minoxidil in FAERS: A Disproportionality Analysis (Analytic Cohort 2012-2025). [PDF]

Life (Basel)
Makkena HB, Kasu V.
europepmc   +1 more source

The decline of iodine therapy in the treatment of Graves' disease in a hospital center: a 20-year analysis. [PDF]

Arch Endocrinol Metab
Silva IB, Carvalho GA, Miasaki FY, Almeida JPI, Sousa MP, Mueller CP, Graf H, Bertolin MD, Mesa Júnior C.   +8 more
europepmc   +1 more source